Table 2.
Drinking Outcomes
| Mean (SD) |
||
|---|---|---|
| Diphenhydramine (n = 7) |
Psilocybin (n = 6) |
|
| % of Heavy drinking days | ||
| Screening | 55.80 (28.40) | 57.93 (34.92) |
|
| ||
| Week 4a | 23.57 (20.29) | 22.64 (14.05) |
|
| ||
| Follow-up b | 16.46 (28.88) | 6.67 (9.52) |
|
| ||
| Open-label c | 7.61 (9.61) | 4.46 (10.09) |
|
| ||
| % of Drinking days | ||
| Screening | 77.00 (24.26) | 84.42 (20.56) |
|
| ||
| Week 4 a | 35.20 (19.52) | 59.52 (19.52) |
|
| ||
| Follow-up b | 28.23 (31.58) | 23.23 (23.46) |
|
| ||
| Open-label c | 18.97 (19.27) | 18.61 (24.15) |
| Drinks per day | ||
| Screening | 4.92 (2.00) | 5.91 (3.11) |
|
| ||
| Week 4 a | 1.99 (1.80) | 2.32 (0.68) |
|
| ||
| Follow-up b | 1.93 (2.76) | 0.74 (0.70) |
|
| ||
| Open-label c | 0.86 (0.94) | 0.50 (0.72) |
a
Represents the 4 weeks prior to administration of study medication.
b
Represents the 32-week double-blind follow-up period.
c
Represents the open-label period.